| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 10 analysts have shared their insights on Kymera Therapeutics (NASDAQ:KYMR), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Kymera Therapeutics and provided 12-month price targets. The average target is $74.1, accompanied by a high estimate of $90.00 and a low estimate of $60.00. This upward trend is apparent, with the current average reflecting a 25.23% increase from the previous average price target of $59.17.
A clear picture of Kymera Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $84.00 | $70.00 |
| Brad Canino | Guggenheim | Announces | Buy | $90.00 | - |
| Jeet Mukherjee | BTIG | Raises | Buy | $75.00 | $59.00 |
| Joseph Catanzaro | Mizuho | Announces | Outperform | $81.00 | - |
| Geoff Meacham | Citigroup | Raises | Buy | $80.00 | $60.00 |
| Jeff Jones | Oppenheimer | Raises | Outperform | $63.00 | $53.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $68.00 | $53.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $70.00 | $60.00 |
| Etzer Darout | Barclays | Announces | Overweight | $60.00 | - |
| Brian Abrahams | RBC Capital | Announces | Outperform | $70.00 | - |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Kymera Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Kymera Therapeutics analyst ratings.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, Kymera Therapeutics faced challenges, resulting in a decline of approximately -55.26% in revenue growth as of 30 June, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Kymera Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -667.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kymera Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.72%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.48%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Kymera Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: KYMR
